地西他滨联合减量HAD方案治疗复发难治性急性髓系白血病临床观察

Clinical observation of Decitabine combined with low-dose HAD regimen in treatment of relapsed or refractory acute myeloid leukemia

目的观察地西他滨(DAC)联合减量HAD方案治疗复发难治性急性髓系白血病(AML)患者的疗效。方法回顾性分析该院16例复发难治性AML患者予以DAC 5 d联合减量HAD方案治疗的过程和转归。结果完全缓解(CR)10例(62.50%),部分缓解(PR)1例(6.25%),总有效率(ORR)为68.75%。总血液学不良反应发生率为100.00%,13例(81.25%)发生感染,3例(18.80%)发生败血症,4例(25.00%)发生轻度肝功能损害,未发生化疗相关死亡。结论 DAC联合减量HAD方案治疗复发难治性AML患者疗效较好。

[Objective ] To evaluate the efficacy and adverse reactions of Decitabine combined with low- dose HAD regimen on relapsed or refractory acute myeloid leukemia. [Methods] The clinical data of 16 diagnosed cases of relapsed or refractory acute myeloid leukemia who were treated with Decitabine combined with low-dose HAD regimen were collected and analyzed. [Resdts] Among the 16 patients, 10 （62.50%） achieved complete remission, 1 （6.25%） achieved partial remission, the total efficiency rate was 68.75%. Hematologic toxicity was 100.00%. The incidence rate of infection was 81.25% （13/16）, and mild liver injury occurred in 4 eases （25.00%）. Treatment-related death was not found. [Conclusion] Decitabine combined with low-dose HAD regimen can effectively treat relapsed or refractory acute myeloid leukemia.